Targeted Protein Degradation Market 2025 – Market Size & Segments Analysis, Industry Trends, Manufacturers Analysis, Opportunities and Forecast 2034

Targeted protein degradation (TPD) is a newly emerging form of drug discovery and therapeutics based on the body’s own proteins degradation pathway to selectively destroy disease proteins. However, the TPD uses specialized bifunctional—and technically ‘degrader’—molecules to recruit specific proteins to the cellular degradation machinery for irreversible removal. This is an especially useful technique for drugs targeting proteins that had previously been described as 'undruggable' for the absence of ideal binding sites suitable for small molecule inhibitors. Core of TPD is the hijacking either ubiquitin-proteasome system (UPS) or lysosomal degradation pathways to degrade unwanted proteins.

Most of it is accomplished by running forward degraders like Lysosome Targeting Chimeras (LYTACs), Proteolysis Targeting Chimeras (PROTACs), and Molecular Glues among others. The emergence of the targeted protein degradation (TPD) market has vastly increased in the past few years. The growth is mainly due to the escalating incidences of chronic disease worldwide, the progress in proteomics, and huge investments in R&D of protein degradation technologies. Consequences of the regulatory process have been streamlined approval by regulatory agencies and have helped to accelerate the adoption of the TPD based therapies by enabling the quicker development and commercialization.

The targeted protein degradation (TPD) market is anticipated to reach USD XXX.X million by 2034 from USD XXX.X million in 2023, at a CAGR of XX.X% during the forecast period 2024-2034.

The increased collaborations between academic institutions and pharmaceutical companies are driving the development of TPD therapies through drug discovery and clinical trials. Additionally, there are several TPD based therapies under clinical trials for treatment of diseases such as cancers and neurodegenerative disorders, which is expected to further boost the targeted protein degradation market during the forecast period 2024-2034.

Growth Drivers:

A major driver for targeted protein degradation market is rising global burden of cancer and neurological diseases. For instance, according to the International Agency for Research on Cancer (IARC), in 2022, there were an estimated 20 million new cancer cases and 9.7 million deaths. Lung cancer was the most commonly occurring cancer worldwide with 2.5 million new cases accounting for 12.4% of the total new cases, and female breast cancer ranked second with 2.3 million cases accounting for 11.6% of the total new cases. TPD technologies like PROTACs, LYTACS, molecular glues and so forth provide a promising approach for treating these diseases by degrading ‘undruggable’ disease causing proteins with traditional inhibitors.

The technological advances in biotechnology & drug discovery have greatly accelerated the targeted protein degradation market. Innovative approaches, such as proteolysis-targeting chimeras (PROTACs), Lysosome-Targeting Chimeras (LYTACs), Autophagy-Targeting Chimeras (AUTACs), and molecular glues among others, have helped boost the capability of TPD to selectively eliminate disease causing proteins. These breakthroughs have opened new avenues for targeting previously undruggable proteins and boosting the possibilities of TPD based therapies.

In targeted protein degradation drug discovery, major pharmaceutical and biotechnology companies are investing large sums of money. Investments by leading pharmaceutical firms such as Pfizer, Bristol Myers Squibb, C4 Therapeutics Inc., are world class and have been made in TPD research through in-house research or strategic partnerships. For instance, on July 22, 2021, Arvinas, and Pfizer Inc., announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The estrogen receptor is a well-known disease driver in most breast cancers. On March 11, 2025, Arvinas and Pfizer announced a positive-topline results from Phase 3, VERITAC-2 clinical trial.

Targeted Protein Degradation Segmentation:

By Degrader Type:

·         Proteolysis-Targeting Chimeras (PROTACs)

·         Lysosome-Targeting Chimeras (LYTACs)

·         Autophagy-Targeting Chimeras (AUTACs)

·         Selective Estrogen Receptor Degraders (SERDs)

·         Molecular Glues

·         Others

By Indication:

·         Oncology

o   Breast Cancer

o   Multiple Myeloma

o   Others

·         Neurology

·         Others

By End-User:

·         ​​​​​​​Hospitals & Clinics

·         Pharmaceutical & Biotechnology Companies

·         Academic & Research Institutes

·         Others

By Region:

·         North America

·         Europe

·         Asia Pacific

·         Latin America

·         Middle East and Africa

Targeted Protein Degradation Market by Degrader Type Review:

Based on the degrader type, the targeted protein degradation market is segmented into six segments including: Proteolysis-Targeting Chimeras (PROTACs), Lysosome-Targeting Chimeras (LYTACs), Autophagy-Targeting Chimeras (AUTACs), Selective Estrogen Receptor Degraders (SERDs), molecular glues, and others. On the basis of degrader type, the Proteolysis-Targeting Chimeras (PROTACs) segment is expected to dominate the market in terms of market share, while the molecular glues segment is also predicted to grow at the highest rate in terms of CAGR during the forecast period.

Targeted Protein Degradation Market by Indication Review:

Based on the indication, the market is segmented into oncology, which is further sub-segmented into breast cancer, multiple myeloma, and others, neurology, and others. On the basis of indication, the oncology segment is expected to be the largest in terms of market share, while the neurology segment is predicted to grow at the highest rate in terms of CAGR during the forecast period.

Targeted Protein Degradation Market by End-User Review:

Based on the end-user, the market is segmented into hospitals & clinics, pharmaceutical & biotechnology companies, academic & research institutes, and others. On the basis of end-user, the pharmaceutical & biotechnology companies segment is expected to be the largest in terms of market share, while the academic & research institutes segment is predicted to grow at the highest rate in terms of CAGR during the forecast period.

Regional Outlook:

The targeted protein degradation market research report offers detailed analysis and forecasts for five major regions i.e., North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.

The North America region is forecasted to maintain its dominant position in the global targeted protein degradation market, accounting for a projected market share of XX.X% in 2023. The regional targeted protein degradation market is mainly driven by the strong investments in pharmaceutical & biotechnology R&D, the presence of leading market players like Arvinas, C4 Therapeutics, Inc., and Nurix Therapeutics, Inc., among others, and a well-established regulatory framework supporting innovative drug development. Furthermore, the rising burden of cancer in North America is driving demand for next-generation targeted therapies like PROTACs and molecular glues. Moreover, North America attracts major venture capital (VC) funding for biotech startups focused on TPD, which is predicted to further drive the targeted protein degradation market in the region during the forecast period 2024-2034.

The region comprising United States and Canada, has witnessed rapid advancements in proteolysis-targeting chimeras (PROTACs), molecular glues, and other protein degradation technologies. North America is the most advanced regional market for targeted protein degradation (TPD) due to its strong research infrastructure, presence of leading market players, and robust investment in pharmaceutical & biotechnology.

Cancer is the second leading cause of death in North America, boosting the demand for TPD based therapies. For instance, according to the American Cancer Society (ACS), in 2024, 2,001,140 new cancer cases and 611,720 cancer deaths are projected to occur in the United States alone.

Furthermore, the US is the largest R&D spender in the global biotechnology sector, accounting for a significant portion of the total global biopharma R&D spending. Moreover, big pharma acquisitions of biotech firms specializing in targeted protein degradation are anticipated in North America, which is expected to further boost the market growth in the region during the forecast period 2024-2034.

Asia-Pacific is the fastest-growing region in the targeted protein degradation market. The regional market growth is majorly driven by the rapid pharmaceutical & biotechnology industry expansion in China, Japan, South Korea, and India among others, rising healthcare expenditure, and the expansion of pharmaceutical R&D capabilities. Furthermore, Asia Pacific region accounts for a significant portion of global cancer cases, creating demand for novel targeted therapies. Moreover, countries like China and Japan have invested heavily in next-generation drug discovery technologies, including TPD, which is expected to further boost the market growth in the Asia Pacific region during the forecast period 2024-2034.

Key Companies in Targeted Protein Degradation Market:

The research report offers a competitive analysis of prominent companies operating in the global targeted protein degradation market. Some of the leading players profiled in the market research report include:

·         Arvinas

·         AstraZeneca

·         Bristol-Myers Squibb Company

·         C4 Therapeutics, Inc.

·         Ranok Therapeutics Co. Ltd.

·         Nurix Therapeutics, Inc.

·         Foghorn Therapeutics

·         Kymera Therapeutics, Inc.

·         Lycia Therapeutics

·         Kangpu Biopharmaceuticals.

·         Biotheryx, Inc.

·         Other Player’s